Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT04110210Phase 1Completed
Phase 1, randomised, open-label trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (2 arms), sponsored by Cairo University. Primary endpoint: Intraoperative and postoperative Opiate consumption at 24 hours. Started Sep 2019; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT04110210.